Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of pomalidomide + bortezomib + low-dose dexamethasone versus bortezomib + low-dose dexamethasone in relapsed or refractory multiple myeloma
MOH_2017-01-05_000032Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing pomalidomide + bortezomib + low-dose dexamethasone with bortezomib + low-dose dexamethasone (2 arms). Started May 2015; status: completed.
02
Drugs
pomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2017-01-05_000032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-05_000032.